The emergence of drugs such as angiotensin receptor-neprilysin inhibitors (ARNI), beta blockers (BB), mineralocorticoid receptor antagonists (MRA), and sodium-glucose cotransporter-2 inhibitors (SGLT2i) has significantly enhanced cardiac function in patients with heart failure, earning them the designation of “new quadruple” therapy for heart failure treatment, which has been incorporated into the guidelines (6). The gene discussed is NR3C2; the disease is heart failure.